Nicholas Opoku

Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial

Nicholas Opoku, Didier Bakajika, Eric M. Kanza et al. · The Lancet · 2018 · 300 citations · Full text

A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection

Kwablah Awadzi, Nicholas Opoku, Simon K. Attah et al. · PLoS neglected tropical diseases · 2014 · 237 citations · Full text

An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana

K. Awadzi, Daniel A. Boakye, G. Edwards et al. · Annals of Tropical Medicine and Parasitology · 2004 · 224 citations

Parasitic Disease, Antiparasitic Agent, Pathology +16

The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data

Hugo C. Turner, Martin Walker, Simon K. Attah et al. · Parasites & Vectors · 2015 · 196 citations · Full text

Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection

Beesan Tan, Nicholas Opoku, Simon K. Attah et al. · PLoS neglected tropical diseases · 2022 · 152 citations · Full text